Literature DB >> 3709030

Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.

A M Glynn, R L Slaughter, C Brass, R D'Ambrosio, W J Jusko.   

Abstract

The disposition of methylprednisolone was examined in six normal subjects after the injection of 20 mg iv methylprednisolone sodium succinate. Disposition studies were performed both without and with ketoconazole, 200 mg/day, for 6 days. Ketoconazole increased the methylprednisolone AUC and mean residence time (by 135% and 66%, respectively) and decreased clearance (60%), the terminal phase slope, and the volume of distribution. These findings are typical of macrolide antibiotic alteration of methylprednisolone disposition and consistent with reports of inhibition of drug metabolism by ketoconazole. Methylprednisolone reduced the 24-hour cortisol AUC by 44%, but morning cortisol concentrations returned to normal. Ketoconazole with methylprednisolone further reduced the 24-hour cortisol AUC and suppressed morning cortisol concentrations. Thus ketoconazole inhibits methylprednisolone disposition and extends the adrenal suppression effects of this corticosteroid.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709030     DOI: 10.1038/clpt.1986.114

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

1.  [Use-risk consideration of anti-infective agents from the point of view of the licensing authority].

Authors:  W Christ; B Esch
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

3.  Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome.

Authors:  Amr El-Husseini; Fathy El-Basuony; Ihab Mahmoud; Ahmed Donia; Hussein Sheashaa; Alaa Sabry; Nabil Hassan; Nagy Sayed-Ahmad; Mohamed Sobh
Journal:  Eur J Clin Pharmacol       Date:  2005-12-23       Impact factor: 2.953

4.  Effects of ciprofloxacin on testosterone and cortisol concentrations in healthy males.

Authors:  N M Waite; D J Edwards; W S Arnott; L H Warbasse
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

5.  Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical data.

Authors:  Constance Loue; Michel Tod
Journal:  AAPS J       Date:  2014-10-02       Impact factor: 4.009

Review 6.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

7.  Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.

Authors:  N Brynne; C Forslund; B Hallén; L L Gustafsson; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

8.  Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man.

Authors:  M A Touchette; P H Chandrasekar; M A Milad; D J Edwards
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

9.  Co-administration of cyclosporine and ketoconazole in idiopathic childhood nephrosis.

Authors:  Amr el-Husseini; Fathy el-Basuony; Ihab Mahmoud; Ahmed Donia; Nabil Hassan; Nagy Sayed-Ahmad; Mohamed Sobh
Journal:  Pediatr Nephrol       Date:  2004-07-06       Impact factor: 3.714

Review 10.  Clinical pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.